| Literature DB >> 29669286 |
Yvona Ward1, Ross Lake1, Farhoud Faraji2, Jamie Sperger3, Philip Martin4, Cameron Gilliard5, Kimberly P Ku3, Tamara Rodems3, David Niles6, Heather Tillman1, JuanJuan Yin1, Kent Hunter2, Adam G Sowalsky1, Joshua Lang3, Kathleen Kelly7.
Abstract
Tumor cells initiate platelet activation leading to the secretion of bioactive molecules, which promote metastasis. Platelet receptors on tumors have not been well-characterized, resulting in a critical gap in knowledge concerning platelet-promoted metastasis. We identify a direct interaction between platelets and tumor CD97 that stimulates rapid bidirectional signaling. CD97, an adhesion G protein-coupled receptor (GPCR), is an overexpressed tumor antigen in several cancer types. Purified CD97 extracellular domain or tumor cell-associated CD97 stimulated platelet activation. CD97-initiated platelet activation led to granule secretion, including the release of ATP, a mediator of endothelial junction disruption. Lysophosphatidic acid (LPA) derived from platelets induced tumor invasiveness via proximal CD97-LPAR heterodimer signaling, coupling coincident tumor cell migration and vascular permeability to promote transendothelial migration. Consistent with this, CD97 was necessary for tumor cell-induced vascular permeability in vivo and metastasis formation in preclinical models. These findings support targeted blockade of tumor CD97 as an approach to ameliorate metastatic spread. Published by Elsevier Inc.Entities:
Keywords: CD97; LPA; adhesion GPCR; circulating tumor cells; metastasis; platelets; transendothelial migration
Mesh:
Substances:
Year: 2018 PMID: 29669286 PMCID: PMC6574118 DOI: 10.1016/j.celrep.2018.03.092
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423